Boulegeris Investments Inc. raised its holdings in Merck & Company, Inc. (NYSE:MRK) by 77.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,252 shares of the company’s stock after purchasing an additional 4,048 shares during the period. Boulegeris Investments Inc.’s holdings in Merck & were worth $593,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Perennial Advisors LLC boosted its position in shares of Merck & by 10.7% in the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after acquiring an additional 157 shares during the period. Stelac Advisory Services LLC bought a new position in shares of Merck & in the second quarter valued at approximately $104,000. Cascade Investment Advisors Inc. boosted its position in shares of Merck & by 15.5% in the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the period. Solaris Asset Management LLC boosted its position in shares of Merck & by 6.3% in the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the period. Finally, Harbour Capital Advisors LLC bought a new position in shares of Merck & in the first quarter valued at approximately $127,000. Hedge funds and other institutional investors own 72.98% of the company’s stock.

WARNING: “Merck & Company, Inc. (MRK) Shares Bought by Boulegeris Investments Inc.” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/merck-company-inc-mrk-shares-bought-by-boulegeris-investments-inc/1720855.html.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at $54.37 on Thursday. The firm has a market cap of $147,855.20, a PE ratio of 13.95, a PEG ratio of 2.34 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Company, Inc. has a 1 year low of $53.63 and a 1 year high of $66.80.

Merck & (NYSE:MRK) last released its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The company’s revenue was down 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.07 EPS. research analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

A number of research firms have recently commented on MRK. upgraded shares of Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 9th. BidaskClub lowered shares of Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. UBS AG lifted their target price on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Barclays PLC lowered shares of Merck & from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $72.00 to $62.00 in a research report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $66.87.

In other news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.25% of the stock is owned by corporate insiders.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.